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Rocaglamides are potent natural anticancer prod-
ucts that inhibit proliferation of various cancer cells
at nanomolar concentrations. We have recently
shown that these compounds prevent tumor growth
and sensitize resistant cancer cells to apoptosis by
blocking theMEK-ERK-eIF4 pathway. However, their
direct molecular target(s) remain(s) unknown. In this
study, using an affinity chromatography approach
we discovered that prohibitin (PHB) 1 and 2 are the
direct targets of rocaglamides. Binding of rocagla-
mides to PHB prevents interaction between PHB
and CRaf and, thereby, inhibits CRaf activation and
subsequently CRaf-MEK-ERK signaling. Moreover,
knockdown of PHB mimicked the effects of rocagla-
mides on the CRaf-MEK-ERK pathway and cell cycle
progression. Thus, our finding suggests that rocagla-
mides are a new type of anticancer agent and that
theymay serve as a small-molecular tool for studying
PHB-mediated cellular processes.
INTRODUCTION
During the past decades, a group of phytochemicals collectively
named rocaglamides (= flavaglines) isolated from the genus
Aglaia (family Meliaceae) have been found to possess anticancer
activities tested in various tumor cell lines as well as in patient
samples in vitro (Kim et al., 2006; Ebada et al., 2011; Zhu et al.,
2007) and to inhibit tumor growth in vivo in several mouse tumor
models (McPhail et al., 1982; Emerson et al., 2010; Lucas et al.,
2009). Aglaia plants consist of approximately 130 species
distributed mainly in the tropical rain forests of Southeast Asia
from Sri Lanka, India, Vietnam, to south China. Several species
of this genus are traditionally used in folk medicine for treatment
of coughs, injuries, asthma, and inflammatory skin diseases. TheChemistry & Biology 19, 1093–110extracts from the Aglaia species are also traditionally used as an
insect repellent (Kim et al., 2006; Ebada et al., 2011).
The first bioactive molecule of Aglaia extracts, rocaglamide
(thereafter refers to Roc-A) (Figure 1A), was identified in 1982,
and was shown to increase the lifespan of tumor-bearing mice
in a leukemia model (McPhail et al., 1982). To date, more than
100 naturally occurring rocaglamide-type compounds, charac-
terized by a cyclopenta[b]-tetrahydrobenzofuran backbone,
have been isolated from over 30 Aglaia species and many of
them have been shown to inhibit tumor growth at nM concentra-
tions (Kim et al., 2006; Ebada et al., 2011). The primary effect of
rocaglamides on tumor growth inhibition was shown to be due to
inhibition of protein synthesis without affecting synthesis of DNA
and RNA (Ohse et al., 1996; Lee et al., 1998).
Although rocaglamides were found to inhibit translation 15
years ago, their mode of action remained largely unknown.
Translation is initiated by binding of the initiation factor eIF4E
to the mRNA 50 cap structure. After binding to the 50 cap struc-
ture, eIF4E interacts with eIF4G, which serves as a scaffold
protein for the assembly of eIF4E and eIF4A to form the eIF4F
complex. The eIF4F complex is then directed to the 50 terminus
of the mRNA, unwinds the mRNA 50 secondary structure to facil-
itate ribosome binding, and promotes ribosome recruitment and
translation (Silvera et al., 2010). Recently, the rocaglamide deriv-
ative silvestrol was shown to inhibit translation by stimulation of
the RNA-binding properties of eIF4A. This action prevents incor-
poration of free eIF4A into the eIF4F complex (Cencic et al.,
2009). We have recently demonstrated that several rocagla-
mides inhibit the mitogen and extracellular-signal regulated
protein kinase kinase (MEK) and extracellular-signal regulated
protein kinase (ERK) signaling (Zhu et al., 2007; Bleumink et al.,
2011). The Ras-mediated MEK-ERK pathway is one of the key
signaling transduction pathways that regulate protein synthesis
and tumor survival (Balmanno and Cook, 2009; Silvera et al.,
2010). We have shown that rocaglamides do not directly inhibit
the translational machinery, but they suppress MEK-ERK
signaling, leading to inhibition of phosphorylation of eIF4E, the
key translation initiation factor that controls the rate-limiting
step of cap-dependent translation (Bleumink et al., 2011;4, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1093
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Figure 1. Rocaglamides-Mediated Inhibition of Proliferation Correlates with Downregulation of ERK Activity
(A) Chemical structures of 13 natural occurring rocaglamides.
(B) Correlation between proliferation inhibition and suppression of ERK activity. Jurkat cells were treatedwith different concentrations of rocaglamides. After 16 hr
treatment, samples were taken for examination of the activation status of ERK bywestern blot. Levels of phosphorylated ERK (pERK1/2) were quantified using the
BIO-1D software (Vilber Lourmat, Marne-la-Valle´e, France). The level of pERK1/2 in DMSO-treated cells is taken as 100%. Cell proliferation rates were deter-
mined after 48 hr treatment by the Cell Titer Glo assay. Concentrations that cause 50% of inhibition (IC50) of cell proliferation are shown. Data are an average of
four independent assays.
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Anticancer Compounds Rocaglamides Target PHB1/2Blagden and Willis, 2011). Consequently, this action does not
only prevent tumor cell growth but also leads to sensitization
to extrinsically induced apoptosis in resistant cancer cells by
downregulation of antiapoptotic proteins (Bleumink et al.,
2011; Giaisi et al., 2012). However, the direct molecular target(s)
of rocaglamides in the ERK signaling pathway remain unknown.
In this study, we carried out an affinity chromatography
approach using rocaglamide-conjugated affinity beads to
identify potential rocaglamide-interacting proteins. Using this
strategy, two rocaglamide-binding proteins, prohibitin 1 (PHB1)
and prohibitin 2 (PHB2), were identified. PHBs are evolutionarily
conserved and ubiquitously expressed proteins that have been
implicated in regulation of diverse cellular processes, such as
mitochondrial biogenesis and function, cell signaling, apoptosis,
survival, and proliferation (Rajalingam and Rudel, 2005; Osman
et al., 2009; Merkwirth and Langer, 2009; Theiss and Sitaraman,
2011). Recently, PHB1 was shown to be involved in regulation of
the Ras-mediated Raf-MEK-ERK signaling pathway (Rajalingam1094 Chemistry & Biology 19, 1093–1104, September 21, 2012 ª201et al., 2005), which plays an important role in regulation of
survival and proliferation in a broad range of human tumors
(Balmanno and Cook, 2009; Silvera et al., 2010). In this study,
we show that rocaglamides bind to both PHB1 and PHB2 and
inhibit their interaction with CRaf. This event leads to inhibition
of PHB/CRaf-mediated activation of the MEK-ERK signaling
pathway and, consequently, inhibits protein synthesis, cell cycle
progression, and cell proliferation in malignant cells.
RESULTS
Rocaglamide-Mediated Inhibition of Proliferation
Correlates with Downregulation of ERK Activity
We have previously shown that several rocaglamide derivatives
suppress the MEK-ERK signaling pathway (Zhu et al., 2007;
Bleumink et al., 2011). To confirm that the antiproliferative effect
of rocaglamides is indeed due to a suppression of the ERK
pathway, we examined 14 rocaglamide derivatives including2 Elsevier Ltd All rights reserved
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Figure 2. Rocaglamides Used for Identification of Potential Cellular Targets
(A) Chemical structures of synthetic rocaglamide derivative FL3 (1), linker-coupled FL45 (2), and NC (3) compounds used in this study.
(B) Effects of Roc-A and FL3 on cell proliferation in cancer cells. Jurkat leukemic cells were incubated with either Roc-A or FL3 for indicated periods. Cell
proliferation was determined by counting the cell numbers (left panel) and by the Cell Titer Glo assay (right panel). Data are representative of two independent
experiments. Means ± SD are shown.
(C) Effects of FL45 and NC on cell proliferation in cancer cells. Jurkat cells were incubatedwith FL45 and NC, followed by examination of cell proliferation as in (B).
Data are representative of two independent experiments. Means ± SD are shown.
Chemistry & Biology
Anticancer Compounds Rocaglamides Target PHB1/2the synthetic FL3 (Thuaud et al., 2009) for their effects on ERK
activity and proliferation (Figures 1A and 2A). The experiment
showed a significant correlation between IC50 values for inhibi-
tion of proliferation and the phosphorylation status of ERK (Fig-
ure 1B). For instance, Roc-AA and Roc-AF did not inhibit cell
proliferation and showed no or very little effect on ERK activity.
Rocaglamides with lower IC50 concentrations for proliferation
inhibition showed stronger suppression of the ERK activities.
These data provide evidence that rocaglamides inhibit cell prolif-
eration by blocking the ERK signaling pathway.
Identification of Prohibitins as Cellular Targets
of Rocaglamide
To investigate the cellular targets of rocaglamides, we first
attempted to identify rocaglamide-binding proteins by affinity
chromatography using rocaglamide-conjugate-coupled Affi-
Gel beads. Therefore, we conjugated the biologically active
derivative FL3 (Thuaud et al., 2009) to a molecular linker to
generate the derivative FL45 (Figure 2A), which was subse-
quently coupled to the Affi-Gel beads. Although FL45 showed
a lesser efficacy compared to Roc-A and FL3, it still maintains
growth inhibitory activity at the nM concentration (Figures 2B
and 2C). A benzyl carbamate of the linker, used as a negative
control (NC), was shown to have no inhibitory activity on prolifer-
ation (Figures 2A and 2C). Total cell extracts from Jurkat cells
were used for the affinity chromatography experiment and two
proteins of approximately 32 and 37 kDa were specifically puri-Chemistry & Biology 19, 1093–110fied on the FL45 beads (Figure 3A). Mass spectrometry (MS)
analysis revealed that the FL45-binding proteins are PHB1 and
PHB2. This was confirmed by western blot analysis using anti-
bodies against PHB1 and PHB2, respectively (Figure 3B).
To confirm that rocaglamides bind to PHB1 and PHB2, the
affinity chromatography experiment was repeated with Flag-
tagged purified PHB1 and PHB2 proteins. The experiment
showed that recombinant Flag-PHB1 and Flag-PHB2 proteins
bind to FL45 but not to the NC beads (Figure 3C). Specificity of
the interaction between PHBs and FL45 was further examined
by adding free Roc-A or Roc-AA as competitors in the affinity
chromatography assay. As expected, Roc-A prevented binding
of PHB1 to FL45, whereas Roc-AA had no effect on binding of
PHB1 to FL45 (Figure 3D). These data demonstrate that PHB1
and PHB2 are the cellular targets of rocaglamides.
Roc-A Inhibits the Interaction between PHB and CRaf
It has been shown that CRaf (= Raf-1) activation requires a direct
interactionwith thePHB1protein (Rajalingamet al., 2005). There-
fore, we further investigated the effect of rocaglamides on inter-
actions between PHB1 and CRaf. Jurkat cells were treated with
either Roc-A or its vehicle (DMSO) for 3 hr. Total cell lysates
were subjected to immunoprecipitation by anti-CRaf antibodies
followed by western blot with antibodies against either PHB1 or
CRaf. Consistent with the previous report (Rajalingam et al.,
2005), CRafwas coprecipitatedwith PHB1.However, in the pres-
ence of Roc-A the interaction between PHB1 and CRaf was4, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1095
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Figure 3. PHB1 and PHB2 Are Direct Targets of Rocaglamides
(A) Purification of rocaglamides-binding proteins by affinity chromatography with FL45-conjugated beads. FL45-conjugated or NC beads were incubated with
total cell lysates from Jurkat cells. The bound proteins were eluted and subjected to SDS-PAGE, visualized by Flamingo Pink, and processed for mass spec-
trometry as described in the Experimental Procedures section.MS analyses revealed the twomajor bands at 32 and 37 kDa (indicated by arrows) being PHB1 and
PHB2, respectively.
(B) The eluted proteins were subjected to western blot with PHB1 and PHB2 antibodies. Data are representative of three independent experiments.
(C) Purified Flag-PHB proteins were used in the affinity chromatography experiment. FL45 or NC beads were incubated with purified Flag-PHB1 and Flag-PHB2
proteins. The bound proteins were eluted and were subjected to western blot using Flag antibody. The input of Flag-precipitated PHB1 and PHB2 is shown on the
right panel.
(D) The experiment in (C) was carried out with Flag-PHB1 in the absence or presence of 50 nM of Roc-A or Roc-AA.
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Anticancer Compounds Rocaglamides Target PHB1/2significantly diminished (Figure 4A). To confirm this observation,
we repeated the experiment using HEK293T cells transiently
transfectedwith Flag-PHB1andFlag-PHB2expressingplasmids
in the absence or presence of Roc-A or Roc-AA. At the cellular
level, PHB1 has been shown to localize to the cell membrane
and the mitochondrial inner membrane together with PHB2
(Nijtmans et al., 2000; Sharma and Qadri, 2004; Merkwirth and
Langer, 2009). The experiment showed that both Flag-PHB1
and Flag-PHB2 were coprecipitated with CRaf. The coprecipita-
tion was abolished by Roc-A, but not by Roc-AA (Figure 4B).
To further confirm above observations, recombinant Flag-
PHB1 and CRaf proteins were mixed in the absence or presence
of Roc-A. PHB1 was immunoprecipitated with a Flag antibody
followed by western blot with Flag and CRaf antibodies. This
experiment clearly showed that in the presence of Roc-A, CRaf
was no longer coprecipitated with PHB1 (Figure 4C). The same
result was obtained using recombinant Flag-PHB2 protein. As
shown in Figure 4D, Roc-A, but not Roc-AA prevented PHB2
interacting with CRaf (Figure 4D). These data demonstrate that
rocaglamides prevent the interaction of both PHB1 and PHB2
with CRaf.
Recently, the marine product aurilide was shown to bind
PHB1, but not PHB2 in the mitochondria, and this interaction
resulted in mitochondrial fragmentation after 4 hr and apoptotic
cell death after 16 hr in HeLa cells (Sato et al., 2011). Therefore,
we also examined the effect of rocaglamides on the mitochon-
drial morphology and apoptosis induction in Jurkat and HeLa
cells. In contrast to aurilide, Roc-A did not cause mitochondrial1096 Chemistry & Biology 19, 1093–1104, September 21, 2012 ª201fragmentation in both cell types (Figure 4E) and did not induce
apoptosis in HeLa cells (data not shown). In Jurkat cells,
a moderate apoptosis induction (less than 20%) was observed
after 36 hr treatment with Roc-A (Zhu et al., 2007). The ineffec-
tiveness of rocaglamides on the mitochondrial morphology
cannot be explained by an inability of rocaglamides to reach
themitochondria as fluorescently labeled FL3was seen to be co-
localized with mitochondria (Figure 4F).
Rocaglamides Inhibit the Raf-MEK-ERK Signaling
Pathway
Since Roc-A inhibits the interaction of PHB with CRaf, we pre-
dicted that rocaglamides may block CRaf activation. To examine
this prediction, Jurkat cells were treated with or without Roc-A
for different periods, and the phosphorylation status of CRaf at
the activating phosphorylation site Ser338 was analyzed by
western blot. As expected, Roc-A inhibited CRaf phosphoryla-
tion in a time-dependent manner and blocked phosphorylation
of the kinases MEK and ERK downstream of CRaf (Figure 5A).
In comparison, Roc-A had no effect on activities of ARaf and
BRaf (Figure 5A).
To further confirm that Roc-A-mediated inhibition of CRaf acti-
vation is due to inhibition of interactions between PHB and CRaf,
we performed a knockdown experiment using specific PHB
siRNAs. Consistent with the above experiment, knockdown of
PHB1 or PHB2 could mimic the inhibitory effect of Roc-A on
CRaf (but not ARaf and BRaf) and the Raf-MEK-ERK pathway
(Figure 5B). Consistent with other studies (Merkwirth et al.,2 Elsevier Ltd All rights reserved
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Figure 4. Roc-A Inhibits Interaction between PHB and CRaf
(A) Roc-A inhibits binding of CRaf to PHB in vivo in Jurkat cells. Jurkat cells were incubated either with Roc-A (50 nM) or solvent DMSO for 3 hr, and CRaf was
immunoprecipitated followed by western blot analysis with PHB1 and CRaf antibodies. Data are representative of two independent experiments.
(B) Roc-A, but not Roc-AA, inhibits binding of CRaf to PHB1/2 in vivo in HEK293T cells. HEK293T cells were transiently transfected with plasmids expressing
Flag-PHB1 and Flag-PHB2. After 24 hr transfection, the cells were treated with solvent DMSO or Roc-A (50 nM) or Roc-AA (50 nM) for 4 hr. CRaf was immu-
noprecipitated followed by western blot analysis with Flag and CRaf antibodies.
(C) Roc-A inhibits the interaction of PHB1with CRaf in vitro. Recombinant CRaf protein was incubated with purified Flag-PHB1 protein in the absence or presence
of Roc-A (100 nM). PHB1 was immunoprecipitated with a Flag antibody followed by western blot using antibodies against CRaf and Flag. Data are representative
of three independent experiments.
(D) Roc-A inhibits the interaction of PHB2 with CRaf in vitro. The experiment was carried out as described in (C) using recombinant Flag-PHB2 in the presence of
either Roc-A or Roc-AA.
(E) Roc-A has no effects on the mitochondrial morphology in Jurkat and HeLa cells. Jurkat and HeLa cells were treated with 50 nM (for Jurkat) and 500 nM
(for HeLa) of Roc-A for indicated periods. Mitochondria were stained by Mito Tracker Red.
(F) Localization of rocaglamides in mitochondria. HeLa cells were treated with fluorescently labeled FL3 (Fluo-FL3, blue) (50 mM). Mitochondria were stained by
Mito Tracker Red.
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Anticancer Compounds Rocaglamides Target PHB1/22008; Sievers et al., 2010), a specific knockdown of either PHB1
or PHB2 at the mRNA level (data not shown) resulted in downre-
gulation of both proteins. This indicates that PHB1 and PHB2
need each other for protein stabilization.
To exclude the possibility that rocaglamides might directly
inhibit Raf activity, we carried out an in vitro assay by incubation
of active Raf with recombinant MEK protein in the absence or
presence of different concentrations of Roc-A. The experiment
showed that all three isoforms of Raf phosphorylated MEK.
However, Roc-A could not block Raf-mediated activation of
MEK (Figure 5C). Thus, rocaglamides do not directly inhibit Raf
activity.Chemistry & Biology 19, 1093–110To further investigate whether rocaglamides inhibit the CRaf-
MEK-ERK signaling pathway upstream of CRaf, we tested the
effect of rocaglamides on ERK activation stimulated by phorbol
myristate acetate (PMA), which is known to indirectly activate
CRaf via activation of protein kinase C (PKC) (Kolch et al.,
1993). The experiment showed that Roc-A failed to inhibit ERK
activity induced by PMA (Figure 5D). Furthermore, we showed
that knockdown of PHB proteins resulted in inhibition of transla-
tion similar to the effect of Roc-A (Figures 5E and 5F). These data
support that rocaglamides inhibit the Raf-MEK-ERK signaling
pathway by interfering with the interaction between PHB and
CRaf.4, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1097
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Figure 5. Knockdown of PHB Mimics the Effect of Roc-A on the CRaf-MEK-ERK Pathway
(A) Roc-A inhibits the CRaf-MEK-ERK signaling pathway. Jurkat cells were treated with Roc-A (50 nM) for different time periods as indicated. Cell lysates were
subjected to western blot with antibodies against total and phosphorylated ARaf, BRaf, CRaf (Ser338), MEK, and ERK. Data are representative of three inde-
pendent experiments.
(B) Knockdown of PHB mimics the effect of Roc-A on the CRaf-MEK-ERK pathway. Jurkat cells were transfected with either control or siRNA specific for PHB1.
Sixty hr after transfection, cells were subjected to western blot analysis using the indicated antibodies. Data are representative of two independent experiments.
(C) Roc-A does not directly inhibit activity of Raf. Activated Raf proteins were incubated with purified MEK protein in the absence or presence of different
concentrations of Roc-A as indicated. The status of phosphorylated MEK was determined by western blot with MEK and phospho-MEK antibodies as indicated.
Data are representative of two independent experiments.
(D) Roc-A does not inhibit PMA-induced activation of ERK. Jurkat cells were stimulated with PMA (5 ng/ml) in the presence or absence of Roc-A (100 nM) for
indicated periods. The activities of ERK were examined by western blot with phospho-ERK antibody as indicated. ERK1 and tubulin antibodies were used for
equal loading control. Data are representative of three independent experiments.
(E) siRNA knockdown of PHB inhibits protein synthesis in malignant cells. Jurkat cells were transfected with control or PHB siRNA. After 72 hr transfection, the
rates of protein synthesis were determined by 35S-methionine incorporation. The efficacies of knockdown were controlled by western blot. Data are repre-
sentative of two independent experiments assayed in triplicates.
(F) Roc-A inhibits protein synthesis in malignant cells. Jurkat cells were treated with different concentration of Roc-A. The rates of protein synthesis were
determined as in (E). Data are representative of two independent experiments assayed in triplicates.
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Anticancer Compounds Rocaglamides Target PHB1/2Knockdown of PHB Mimics the Effect of Rocaglamides
on Cell Cycle Progression
To further investigate the role of PHB in regulation of cell prolifer-
ation, the effects of Roc-A and PHB siRNA on the cell cycle were
assayed in Jurkat cells. Treatment of Jurkat cells with Roc-A
arrested cell cycle at the G0/G1 phase (Figures 6A and 6B). In
addition, the expression levels of proteins important for the
G1-S transition, such as cyclin D3, CDK4, CDK6, and cdc25A1098 Chemistry & Biology 19, 1093–1104, September 21, 2012 ª201(Boutros et al., 2007; Malumbres and Barbacid, 2009), were
strongly downregulated by Roc-A (Figure 6C). In contrast, the
expression levels of cdc25C and CDK1, which are mainly
involved in driving the transition from S to G2/M phase (Boutros
et al., 2007; Malumbres and Barbacid, 2009), were unchanged
(Figure 6C). Similar to the effect of Roc-A, knockdown of PHB1
and PHB2 in Jurkat cells by siRNA led to inhibition of cell cycle
progression at the G1/S phase via downregulation of the G1/S2 Elsevier Ltd All rights reserved
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Figure 6. siRNA Knockdown of PHB Mimics the Effect of Roc-A on Cell Cycle Progression
(A) Roc-A induces cell cycle arrest at the G0/G1 phase accompanied with reduction in S phase in Jurkat cells. Jurkat cells were treated with 50 nM of Roc-A or
DMSO as indicated. Cell cycle distributions were determined after 24 hr treatment.
(B) Data from (A) are presented by bar charts. The results are representative of three independent experiments. Means ± SD are shown.
(C) Roc-A downregulates expression of G1/S phase regulatory proteins in Jurkat cells. The cells from (A) were subjected to western blot for examination of the
expression levels of proteins controlling the G1/S phase. Data are representative of three independent experiments.
(D) siRNA knockdown of PHB results in blocking of cell cycle progression similar to Roc-A. Jurkat cells were transfected with PHB1/2 siRNAs. After 24 hr of
transfection, the status of cell cycle was determined as in (A).
(E) Data from (D) are presented by bar charts. The data are representative of two independent experiments. Means ± SD are shown.
(F) siRNA knockdown of PHB results in reduced expression of G1/S regulatory proteins. The data are representative of two independent experiments.
See also Figure S1.
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6D–6F). Thus, knockdown of PHB proteins can mimic the effect
of Roc-A on cell cycle progression.
Above data suggest that rocaglamides exert their antiprolifer-
ative effect by interfering with PHB function. Along this line, over-
expression of PHB proteins would be expected to render the
cells more resistant to rocaglamide. To study this prediction,
Jurkat cells were transiently transfected with either the Flag-
control or the Flag-PHB1 and Flag-PHB2 expression plasmids
and the effects of Roc-A on proliferation of the transfected cells
were examined. The experiment showed that Jurkat cells trans-
fected with Flag-PHB1/2 expression plasmids proliferated faster
than the cells transfected with the control plasmid (Figure S1A
available online). As predicted, overexpression of Flag-PHB1/2
rendered Jurkat cells more resistant to Roc-A (Figure S1B).
However, the Flag-PHB-mediated resistance was not as strong
as expected. This might be due to the difference between Flag-
PHB and the wild-type PHB proteins.Chemistry & Biology 19, 1093–110Rocaglamides Prevent PHB-CRaf Membrane
Association
PHBwas previously shown to be required for membrane associ-
ation and activation of CRaf (Rajalingam et al., 2005). Therefore,
we asked whether rocaglamides affect PHB-CRaf membrane
association. To investigate this question, cell membrane and
cytosol fractions were prepared from Jurkat cells treated with
either Roc-A or Roc-AA to analyze the localization of PHB and
CRaf. Western blot analysis showed a significant reduction
in CRaf, particularly phosphorylated CRaf (pSer338), in the
membrane fraction after Roc-A treatment (Figure 7A). Interest-
ingly, Roc-A also significantly reduced the levels of PHB in the
membrane fraction indicating that binding of rocaglamides
to PHB may also interfere with PHB membrane association.
However, Roc-A did not influence Ras membrane localization
(Figure 7A). These results further demonstrate that rocaglamides
block the CRaf-MEK-ERK signaling pathway by interfering with
the PHB function (Figure 7B).4, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1099
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Figure 7. Roc-A Prevents PHB-CRaf Membrane Localization
(A) Analysis of PHB-CRaf membrane localization in Jurkat T cells in the presence of Roc-A or Roc-AA. Jurkat cells were treated with 100 nM of Roc-A or Roc-AA
for 16 hr. Whole-cell lysates and fractions of cell membrane and cytosol were prepared and were subjected to western blot analysis with antibodies as indicated.
Phospho-CRaf (Ser338) was used as marker of activity and tubulin as loading control. Results are representative of two independent experiments.
(B) Schematic representation of the mechanism by which rocaglamides inhibit the Raf-MEK-ERK pathway.
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We previously found that ERK activity is downregulated by
different rocaglamide derivatives in malignant cells, but not in
normal cells (Zhu et al., 2007). Recently, we demonstrated that
rocaglamides inhibit protein synthesis primarily via blocking the
MEK-ERK-Mnk-eIF4E signaling pathway (Bleumink et al., 2011).
However, the direct molecular targets of rocaglamides in the
ERK signaling pathway were unknown.
In the present study, using affinity chromatography, we show
that rocaglamides bind directly to PHB1 and PHB2. This is
further confirmed by using purified recombinant PHB proteins
in the affinity chromatography assay (Figure 3). PHB1 was previ-
ously shown to interact with CRaf, and this interaction was
necessary for CRaf activation by Ras (Rajalingam et al., 2005).
Consistent with the previous study, we confirm that PHB1 inter-
acts with CRaf and demonstrate that binding of rocaglamides to
PHB1 proteins prevents interaction between PHB1 and CRaf
(Figures 4A–4D). In addition, we show that PHB2 also binds to
CRaf and that this interaction is blocked by rocaglamides, too
(Figures 4B and 4D). We further show that binding of rocagla-
mides to PHB proteins or targeting PHB by siRNAs inhibits
CRaf phosphorylation and consequently suppresses translation,
cell cycle progression, and cell proliferation in malignant cells
(Figures 5 and 6). Furthermore, we show that rocaglamides do
not only inhibit interaction of PHB and CRaf, but also interfere
with PHB and CRaf membrane association (Figure 7A). Taken
together, our study reveals the molecular mechanism of the anti-
cancer action of rocaglamides (Figure 7B).
Activation of the Ras-Raf-MEK-ERK pathway has been shown
to be associated with proliferation in a broad range of human
tumors (Maurer et al., 2011; Balmanno and Cook, 2009; Silvera
et al., 2010), which makes this pathway an important molecular1100 Chemistry & Biology 19, 1093–1104, September 21, 2012 ª201target of anticancer therapy (Sebolt-Leopold and English,
2006; Roberts and Der, 2007). Recently, treatment with small-
molecule inhibitors of BRaf has been shown to yield unprece-
dented response rates of 70%–80% as single agents in
melanoma patients with BRafV600E mutation (Bollag et al.,
2010; Flaherty et al., 2010; Kefford et al., 2010). However, selec-
tive inhibition of BRaf has been found to drive Ras-dependent
activation of CRaf and MEK-ERK signaling leading to drug resis-
tance and even to drug-mediated tumor progression (Heidorn
et al., 2010; Halaban et al., 2010; Kwong and Chin, 2010). We
show that rocaglamides specifically inhibit CRaf activation by
preventing interaction between PHB and CRaf. So far, small
molecules specifically inhibiting CRaf activity have not been
reported. Thus, rocaglamides may be used in combination with
BRaf inhibitors to enhance efficacies of cancer therapy and to
overcome drug-resistance. We also show that rocaglamides
do not directly inhibit Raf activity. Instead, rocaglamides inhibit
CRaf activation by Ras via preventing the interaction of CRaf
and PHB. This suggests that rocaglamides are new types of
inhibitors of the Raf-MEK-ERK signaling pathway and may serve
as a novel anticancer agent.
PHB has previously been reported to play a regulatory role in
thePI3K-Akt signaling pathway via interactionwith phosphatidyl-
inositol 3,4,5-triphosphate and Akt (He´ron-Milhavet et al., 2008;
Ande and Mishra, 2009). The PI3K-Akt signaling pathway is
inappropriately activated in many cancers, which promotes
protein synthesis and proliferation (Engelman, 2009). The activity
of the translation initiation factor eIF4E is also regulated by
the PI3K-AKT-mTOR pathway (Silvera et al., 2010). We have
recently demonstrated that rocaglamides do not inhibit mTOR
phosphorylation (Bleumink et al., 2011). Thus, rocaglamides
inhibit protein synthesis primarily via blocking the MEK-ERK-
Mnk-eIF4E signaling pathway.2 Elsevier Ltd All rights reserved
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first mammalian PHB (PHB1) was identified in 1989 as a
potential tumor suppressor with antiproliferative activity and
was hence named prohibitin (McClung et al., 1989). However,
the antiproliferative activity was found to be attributed to the
30-UTR of the PHB1 mRNA, and it is unrelated to the function
of the protein itself (Jupe et al., 1996). The role of PHB1 in cancer
proliferation and/or tumor suppression has been controversially
discussed. Increased PHB1 levels have been reported in
cancers of cervix, esophagus, stomach, breast, lung, bladder,
thyroid, ovary, and prostate, indicating its potential role in cancer
progression (Theiss and Sitaraman, 2011). However, opposing
results have also been observed, e.g., decreased PHB1 levels
in gliomas and somatic mutations in the PHB1 gene in a few
sporadic breast cancers (Theiss and Sitaraman, 2011). Our
data show that rocaglamides inhibit CRaf activation and, conse-
quently, cell proliferation in leukemic cells. In addition, knock-
down of PHB via siRNA resulted in inhibition of cell cycle
progression of Jurkat cells. Thus, our study supports an essential
role of PHB in regulation of cancer proliferation.
Recently, the marine product aurilide was shown to selectively
bind to PHB1 in the mitochondria leading to rapid (after 4 hr)
mitochondrial fragmentation and apoptosis induction after
16 hr in HeLa cells (Sato et al., 2011). In contrast, rocaglamides
bind both PHB1 and PHB2, and this interaction does not target
mitochondria for degradation in both Jurkat and HeLa cells
(Figure 4D). Since PHBs also regulate cell cycle progression,
transcriptional regulation and cellular signaling in other cellular
compartments depending on the cell type (Mishra et al., 2005,
2010; Artal-Sanz and Tavernarakis, 2009), our finding of direct
binding of rocaglamides to PHBs also suggests that these
compounds may serve as a new molecular probe for studying
PHB-mediated cellular processes.
SIGNIFICANCE
To improve cancer treatment, there is an urgent need to
better understand signaling in cancer cells and to develop
new anticancer drugs. Although the ability of the natural
compounds rocaglamides to inhibit tumor cell proliferation
was discoveredmore than 15 years ago, theirmode of action
has been elusive. We have recently shown that rocagla-
mides suppress the MEK-ERK-Mnk1 signaling pathway,
which is one of the key pathways that regulate protein
synthesis, proliferation, and tumor survival. However, the
direct target(s) remained unknown. In this study, we found
that the direct molecular targets of rocaglamides are PHB1
and PHB2. Binding of rocaglamides to PHBs prevents their
interaction with CRaf and, thereby, inhibits CRaf activation
and Raf-MEK-ERK-mediated cell cycle progression and
cell proliferation in cancer cells. So far, small molecules
specifically inhibiting CRaf activity have not been reported.
Thus, rocaglamides may serve as a new type of anticancer
agent. The role of PHB1 in cancer proliferation and/or tumor
suppression has been controversially discussed because
both overexpression and reduced expression or deletion/
mutations in the PHB1 gene have been reported in human
tumors. We show that targeting PHB1 or 2 via siRNAmimics
the inhibitory action of rocaglamides on CRaf activation andChemistry & Biology 19, 1093–110proliferation. Thus, our study supports the important role of
PHBs in regulation of cancer proliferation. Furthermore, as
PHB proteins are involved in regulation of several important
signaling pathways in different cellular compartments, our
finding also suggests that rocaglamides may serve as
a new small-molecular tool for studying PHB-mediated
cellular processes.
EXPERIMENTAL PROCEDURES
Rocaglamide Derivatives
Roc-A (rocaglamide) (>98% pure) was purchased from Enzo Life Sciences
(Lo¨rrach, Germany). FL3 and fluorescently labeled FL3 was described previ-
ously (Thuaud et al., 2009). The other rocaglamidederivatives used in this study
areRoc-AA (C-1-O-acetyl-methylrocaglate) (Chaidir et al., 1999); Roc-AB (1-O-
acetyl-rocaglamide) (Hiort et al., 1999); Roc-AF (30,40-methylendioxy-methylro-
caglate) (Cui et al., 1997); Roc-AG (aglaroxin A) (Dreyer et al., 2001; Molleyres
et al., 1999); Roc-AL (40-demethoxy-30,40-methylenedioxyrocaglaol) (Cui
et al., 1997); Roc-AR (1-oxo-40-demethoxy-30,40-methylenedioxyrocaglaol)
(Cui et al., 1997); Roc-D (C-30-hydroxyrocaglamide) (Nugroho et al., 1997);
Roc-I (C-1-O-acetyl-30-hydroxy-rocaglamide) (Nugroho et al., 1997); Roc-J
(30-hydroxyaglafoline) (Nugroho et al., 1999); Roc-Q (demethylrocaglamide)
(Ishibashi et al., 1993; Dumontet et al., 1996); Roc-U (methylrocaglate, aglafo-
line) (Ishibashi et al., 1993; Dumontet et al., 1996); and Roc-W (C-1-O-acetyl-
desmethylrocaglamide) (Hiort et al., 1999). All compounds had been isolated
previously from various Aglaia species (see above cited literature) and are
>98% pure assessed by high-performance liquid chromatography (HPLC).
Cell Lines and Culture
The human T cell leukemic cell line Jurkat, the human embryonic kidney cell
line HEK293T, and the human cervical cancer cell line HeLa were used in
this study. Cells were cultured in Roswell Park Memorial Institute 1640 or
Dulbecco’s modified Eagle’s medium, respectively, and supplemented with
10% fetal calf serum, 100 U/ml penicillin (Gibco, Invitrogen, Darmstadt,
Germany), 100 mg/ml streptomycin (Gibco, Invitrogen), and 2 mM L-glutamine
(Gibco, Invitrogen) at 37C and 5% CO2.
Cell Proliferation Assay
Cells were treated with different doses of rocaglamides (solved in DMSO) for
indicated times. Cell proliferation was determined by counting the cell
numbers and by using the Cell Titer Glo cell viability assay kit according to
the manufacturer’s instructions (Promega, Mannheim, Germany).
Western Blot Analysis and Immunoprecipitation
For western blot analysis, 1 3 106 cells were lysed as previously described
(Zhu et al., 2007). Equal amounts of proteins were separated on 5%–13%
SDS-PAGE depending on the molecular sizes of the proteins and blotted
onto a nitrocellulose membrane (Amersham Biosciences, Little Chalfon, UK)
as previously described (Zhu et al., 2007). Subcellular fractionations were
carried out as described previously (Kaminski et al., 2012). The following anti-
bodieswere used: anti-PHB1 andanti-PHB2were kindly providedbyV.Bosch;
anti-CDK2 was kindly provided by I. Hoffmann; antibodies against Ras, ARaf,
BRaf, CRaf, MEK, PHB1, phospho-ARaf (S299), phospho-BRaf (S445), phos-
pho-CRaf (S338), phospho-MEK, cdc25C (5H9), CDK4, CDK6, and Cyclin D3
were purchased from Cell Signaling Technology (Danvers, MA, USA); cdc25A
Ab3 (Clone DCS-120 + DCS-121) from Neomarkers (Thermo Scientific, Corn-
wall, UK); CDK1 from Exbio (Prague, Czech Republic); ERK1 from BD Biosci-
ences (Erembodegem, Belgium); FLAG and Tubulin from Sigma-Aldrich (St.
Louis, USA); and pERK fromSantaCruz Biotechnology (Heidelberg, Germany).
For immunoprecipitation, cells were washed in ice-cold PBS and lysed in
buffer containing 10 mM Tris-HCl pH 7.5, 300 mM NaCl, 1% NP-40, and
10% glycerin and protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany). Lysates were cleared by centrifugation for 30 min at 10,000 g. After
addition of an equal volume of buffer containing 10 mM Tris-HCl pH 7.5, 1%
NP-40, and 10% glycerin and protease inhibitor cocktail, supernatants were
incubated with indicated antibodies and sepharose-coupled protein A beads
overnight.4, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1101
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To identify rocaglamide-interacting proteins, affinity chromatography was
performed using Affi-Gel-10 agarose beads (Bio-Rad Laboratories, Hercules,
CA, USA) covalently coupled to the chemically synthesized rocaglamide deriv-
ative FL45 (the coordinate to the compound 6 is described in Thuaud et al.,
2009) or to NC, an inactive derivate. Coupling of the compound FL45 to Affi-
Gel-10 was performed according to the manufacturer’s instructions.
Briefly, 500 ml of packed Affi-Gel-10 were washed with isopropanol and
dimethylformamide (DMF). Subsequently, 400 ml of 12 mM FL45 or NC dis-
solved in DMF supplemented with 2.5% (v/v) triethylamine were added. This
suspension was gently rotated at room temperature (RT) for 12 hr. After block-
ing of any remaining active ester groups using aminopropanol for 4 hr, the
matrix was thoroughly washed with DMF, ethanol, and H2O. Coupled Affi-
Gel-10 agarose beads were kept in PBS supplemented with 0.02% NaN3 at
4C until further use.
Affinity Chromatography
For affinity chromatography, 1 3 108 Jurkat cells were washed in PBS and
lysed in 2 ml lysis buffer containing 50 mM Tris/HCl pH 8.0, 120 mM NaCl,
1% NP-40, 5 mM DTT, 200 mM Na-orthovanadate, 25 mM NaF, and protease
inhibitor cocktail (Roche Diagnostics). Cellular debris was removed by
centrifugation at 10,000 g for 30 min. 500 mg of total protein extract was
incubated for 12 hr at 4C with 40 ml of FL45, NC-coupled or uncoupled
Affi-Gel beads. The beads were extensively washed with lysis buffer, and
bound proteins were eluted and reduced in a sample buffer containing
63 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol, a trace bromophenol
blue, and 200 mM DTT for 30 min at 65C. After cooling on ice, the
sample was alkylated with a final concentration of 150 mM iodacetamide
for additional 30 min. Proteins were separated by SDS-PAGE (10% gel) in
Protean II electrophoresis units (Bio-Rad Laboratories) and visualized by
Flamingo Pink (Bio-Rad Laboratories) following the manufacturer’s instruc-
tions. Two major protein bands at approximately 32 and 37 kDa were
detected by fluorescence scanning using a Typhoon Trio Laser Scanner (GE
Healthcare, Munich, Germany) in FL45, but not control samples (Figure 3A).
Nevertheless, same sections of the gel were picked in the NC to ensure
a specific identification in the FL45 eluents. These bands were picked auto-
matically using an Ettan spotpicker (GE Healthcare), manually processed for
MS by tryptic digestion, and spotted onto steel grids as described elsewhere
(Schmidt et al., 2008).
MS Analysis
The samples were analyzed by peptide mass fingerprinting using the 4700
Proteomics Analyzer mass spectrometer (Applied Biosystems, Framingham,
MA, USA). For MS analyses, typically 1,000 shots were accumulated in
positive reflector mode for each spot. In addition, MS/MS analysis was used
for validation of the probability mass function. Therefore, precursor ions
were selected automatically according to the following criteria: a maximum
of five masses per spot and a signal-to-noise ratio >35. The precursor
mass window was set to 50 (full width at half maximum). All peptide mass
spectra were processed by internal calibration with autolytic fragments of
porcine trypsin with 25 ppm mass tolerance using the GPS Explorer software
version 3.6 (Applied Biosystems). Mass spectrometric data were searched
against the NCBI database with a taxonomy restriction to human proteins
(216,738 entries, November 11, 2009) using MASCOT V2.0 (Matrix Sciences,
London).
Analysis of Mitochondrial Morphology
For Jurkat cells, 13 106 cells were treated with or without Roc-A for indicated
periods and then stained for 15 min with 50 nM of MitoTracker Deep Red FM
(Invitrogen). Cells were washed twice with PBS, fixed with 3% paraformalde-
hyde for 10 min at 37C in the dark, and permeabilized with 90%methanol for
a minimum of 30 min at 4C or left overnight at 20C. The fixed and permea-
bilized cells were washed three times, transferred to microscopy slides, and
the mitochondrial morphology was examined at the Zeiss LSM710 micro-
scope (Zeiss, Jena, Germany). For HeLa cells, cells were grown onmicroscopy
chamber slides (Lab-Tek, Thermo Scientific) and treated with Roc-A and mito-
Tracker as described in Jurkat cells. After washing twice with PBS, cells were
fixed with 4% paraformaldehyde for 15 min at RT in the dark. After additional1102 Chemistry & Biology 19, 1093–1104, September 21, 2012 ª201washing steps, cells were subjected to permeabilization with 0.2% Triton X-
100 for 10 min at RT in the dark. After washing, cells were examined at the
Zeiss LSM710 microscope. The fluorescently labeled FL3 was described
previously (Thuaud et al., 2009).
Knockdown Experiment
Jurkat cells (2 3 106) were transfected in Nucleofector solution (Nucleofector
kit V, Amaxa Biosystems, Cologne, Germany) with 1–2 mM of nonsense siRNA
(QIAGEN, Hilden, Germany) or siRNAs specific for PHB1 (50-CAGAAAUCACU
GUGAAAUUTT-30 [QIAGEN]) or PHB2 (50-CCCAGGAAUUCUCAAUAAATT-30
[QIAGEN]) using the Amaxa Nucleofector apparatus and the program X-01.
Cells were collected at indicated time points after transfection for cell cycle
measurement, translation assays, and protein expression analysis.
Plasmids and Transfections
Expression plasmids for Flag-PHB1 and Flag-PHB2 have been described and
were kindly provided by V. Bosch (Emerson et al., 2010). As Flag-control
plasmid PP4R1 tagged with Flag was used. The expression plasmids were
transfected into HEK293T cells using the standard calcium phosphate
method. Flag-PHB1 and Flag-PHB2 proteins were purified from HEK293T
by immunoprecipitation using a Flag antibody and Flag-peptide elution. For
Jurkat cells, transfection was carried out with Nucleofector solution (Nucleo-
fector kit V, Amaxa Biosystems).
In Vitro Binding Assay
For in vitro binding assays, purified Flag-PHB1 or Flag-PHB2 protein was incu-
bated with recombinant CRaf protein in the presence or absence of 100 nM
Roc-A for 2 hr. Subsequently, PHB1 or PHB2 was immunoprecipitated using
a Flag antibody. The recombinant human CRaf (RAF1) expressed by baculovi-
rus in Sf9 insect cells using an N-terminal glutathione S-transferase tag
(GTX65339) was purchased from GeneTex (Irvine, CA, USA). The gene acces-
sion number is NM_002880. The purity was determined to be >85% by
densitometry.
In Vitro Kinase Assay
To obtain activated Raf, Jurkat T cells were stimulated with PMA for 2 hr, and
the cells were subjected to immunoprecipitation with antibodies against
different Raf proteins. To examine the effect of rocaglamides on Raf activity
in vitro, immunoprecipitated Raf was incubated with or without Roc-A for
10 min, and then recombinant MEK proteins (Upstate Biotechnology, Lake
Placid, NY, USA) were added and further incubated for 30 min at 30C. The
status of activatedMEKwas examined by western blot with antibodies against
MEK and pMEK.
Cell Cycle Determination
For cell cycle analysis, approximately 1 3 106 cells were collected, lysed in
150 ml of Nicoletti-buffer (0.1% Na-citrate, 0.1% Triton X-100, and 50 mg/ml
propidium iodide), and stored at 4C overnight in the dark. The propidium
iodide stained DNA fragments were quantified by flow cytometry (FACSCanto
II, BD Biosciences). The ModFit LT program was used for the cell cycle
analysis.
Translation Assay
Protein synthesis was estimated by measuring the amount of incorporated
35S-methionine. Briefly, cells (1 3 106) were incubated for 3 hr in methio-
nine-free medium. Then 7 mCi per well of 35S-methionine-labeling mix
(PerkinElmer, Waltham, MA, USA) were added. After 2–6 hr incubation, cells
were washed with PBS and lysed in ice-cold lysis buffer for 15 min on
ice and centrifuged (10 min, 13,000 rpm). Then, 50 ml of each lysate was
incubated in 1 ml of Liquid Scintillation Cocktail solution (Beckman Coulter,
Brea, CA, USA), and radioactivity was determined with Liquid Scintillation
counting.
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